MedTrace Logo

Part 2 on the Study Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children (COVILLE2) (WHO)

NCT04416893 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2021-05-27

No results posted yet for this study

Summary

France and in particular the paris area was one of the countries most affected by the pandemic Covid19.

School closures and a generalized lockdown of the population were instituted in France from 17 March 2020 to 10 May 2020. Schools and nurseries have reopened partially since 11 May 2020. From 2 June, this reopening is more widespread. By combining the search for SARS-Cov2 viruses by PCR and micro-method serology we will be able to evaluate both the infection at a given time and also older contact with SARS-CoV2.

The temporal knowledge of the prevalence of SARS-Cov2 carriage and the serological status (IgM and IgG) after return to the community are crucial information to evaluate the speed of spread of the virus in children. This is the objective of COVILLE2, phase 2 of the COVILLE study.

Conditions

  • COVID19

Interventions

DIAGNOSTIC_TEST

RT-PCR SARS-Cov2

nasopharyngeal swab will be taken for detection of SARS-CoV-2 by RT-PCR

DIAGNOSTIC_TEST

Sars-Cov2 serology

A microsample of blood will be taken for serology

Sponsors & Collaborators

  • Association Clinique Thérapeutique Infantile du val de Marne

    collaborator OTHER

  • Groupe de Pathologies Infectieuses Pédiatriques (GPIP)

    collaborator OTHER

  • Francophone Pediatric Resuscitation and Emergency Group (GFRUP)

    collaborator OTHER

  • Centre Hospitalier Intercommunal Creteil

    lead OTHER

Eligibility

Max Age
15 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-30
Primary Completion
2021-01-31
Completion
2021-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04416893 on ClinicalTrials.gov